Практические Рекомендации По Лекарственному Лечению Рака Предстательной Железы

Nosov, Dmitry; Волкова, М. И.; Gladkov, Oleg; Карабина, Е. В.; Krylov, Vadim; Матвеев, В. Б.; Mitin, Timur; Popov, A. M.

doi:10.18027/2224-5057-2020-10-3s2-33

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Кастрационная резистентность служит своеобразным предиктором метастазирования, и ее своевременная диагностика представляется одной из главных задач лечения пациентов с РПЖ. В контексте современной, эффективной и безопасной терапии интерес представляют нестероидные антиандрогены нового поколения [24,25].…”

Section: материалы и методыunclassified

“…На основании данных этих крупных исследований у пациентов с нмКРРПЖ и высоким риском развития метастазирования назначение ингибиторов андрогенных рецепторов (апалутамида, энзалутамида) на фоне продолжающейся АДТ является терапией выбора [22][23][24][25].…”

Section: таблица 7 лабораторные показателиunclassified

“…Стоит отметить, что у 34 % мужчин с нмКРРПЖ использовалась максимальная андрогенная блокада антиандрогенами 1-го поколения, что не отвечает современным международным и российским стандартам лечения [22][23][24][25].…”

Section: таблица 7 лабораторные показателиunclassified

See 2 more Smart Citations

Epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia

et al. 2022

View full text Add to dashboard Cite

Aim. To study the clinical and demographic profile of patients with non-metatstatic castration-resistant prostate cancer (nmCRPC) and clinical approaches to the treatment of nmCRPC in the context of daily medical practice before and after progression M1 stage.Materials and methods. The multicenter non-interventional epidemiological study were included 200 patients with a documented diagnosis of nmCRPC from 2019 to 2020. Each patient visited twice: start and after 6 months. Of the 200 patients included, 9 were excluded from the analysis presented in this article: 1 patient had no information on inclusi- on criteria, 1 patient did not meet the inclusion criteria, 7 patients did not attend visit 2. Thus, data are presented for 191 patients.Results and conclusion. The median age was 74.3 years (range 55 to 91). 72 % (137/191) had a disability group. The most common comorbidities were hypertension (n = 115) and hypercholesterolemia (n = 56). The median time from the diagnosis of prostate cancer to the development of castration resistance (diagnosis of nmCRPC) was 75 months. Prostate specific antigen (PSA) nadir (0.37 ng/ml on average) was achieved after 15 months of prostate cancer therapy (median time to reach PSA nadir). At the same time, PSA doubling time in most cases (47.6 %; 91/191) was less than 6 months, 18.8 % of persons (36/191) had PSA doubling time for more than 10 months.

show abstract

Section: материалы и методыunclassified

Section: таблица 7 лабораторные показателиunclassified

See 1 more Smart Citation

Epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Диагноз, как правило, строится на совокупности клинических и морфологических данных, таких как результаты пальцевого ректального исследования, гистологического исследования микропрепаратов, полученных в ходе мультифокальной биопсии предстательной железы (ПЖ), сывороточная концентрация простатического специфического антигена (ПСА), а также по данным, полученным при компьютерной и/или магнитно-резонансной томографии органов малого таза [2]. В некоторых случаях первичная оценка распространенности опухолевого процесса может быть дополнена методами радионуклидной диагностики.…”

Section: Introductionunclassified

“…1 Mann-Whitney U test. 2 Cochran-Armitage test for trend. 3 С помощью модели пропорциональных рисков Кокса проведен анализ БРВ в группе больных локализованным РПЖ.…”

Section: Introductionunclassified

Prostate-specific antigen density as a predictor of recurrence-free survival following combined hormonal-radiation therapy of localized prostate cancer

et al. 2022

View full text Add to dashboard Cite

Background. Prostate cancer is amongst one of the most prevalent cancers in men worldwide. Combined hormonal-radiation therapy has become a standard of care for localized prostate cancer definitive treatment. As many as 30 % of men are at risk for disease progression within 10 years following radical treatment.Aim. To assess the significance of prostate-specific antigen (PSA) density as a predictor of recurrence-free survival following combined hormonal-radiation therapy in patients with localized prostate cancer.Materials and methods. We conducted a retrospective study of 272 patients with clinically localized prostate cancer treatment results who received combined hormonal-radiation therapy between January 1996 and December 2016.Results. On the basis of our study, we confirmed high prognostic value of PSA density among patients with localized prostate cancer who received combined hormonal-radiation treatment. We utilized ROC-analysis in order to determine the threshold value of the PSA density index – 0.376 ng/ml/cm3, exceeding of which was associated with statistically significant reduction in the recurrence-free survival rate. The area under the curve was 0.711 (95 % confidence interval 0.653–0.764; p <0.0001). The risk of recurrence increased with rising of PSA density.Conclusion. PSA density has proven to be a reliable tool for assessing the risk of prostate cancer recurrence among patients with localized prostate cancer who have undergone combined hormonal-radiation therapy.

show abstract

Modern possibilities of application <sup>99m</sup>Tc-labeled prostate-specific membrane antigen ligands in prostate cancer

et al. 2022

View full text Add to dashboard Cite

This article presents a modern possibilities and future path of prostate-specific membrane antigen (PSMA) radiopharmacuticals labeled by 99mTc, that is the most popular isotope using in conventional nuclear medicine. The main advantages and disadvantages of SPECT/CT with these radiopharmaceuticals in different phases of prostate cancer continuum have been analyzed. Results of research diagnostic sensitivity of 99mTc-PSMA SPECT/CT including comparison with 68Ga-PSMA PET/CT and conventional modality such as MRI and bone scan are presented. The prerequisites of application 99mTc-labeled PSMA ligands in PSMA-guided surgery, methodology of PSMA-guided surgery and foreign authors application experience are presented in this article too.

show abstract

Практические Рекомендации По Лекарственному Лечению Рака Предстательной Железы

Abstract: .

Cited by 4 publications

References 0 publications

Epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia

Epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia

Prostate-specific antigen density as a predictor of recurrence-free survival following combined hormonal-radiation therapy of localized prostate cancer

Modern possibilities of application <sup>99m</sup>Tc-labeled prostate-specific membrane antigen ligands in prostate cancer

Contact Info

Product

Resources

About